NRX Pharmaceuticals Inc.-CW22NRXPWPreferred / convertible
13F holders, Q3 2024 (September 30)8holders +2
2new positions
0sold out
$0.05avg. 13F price*
At the end of Q3 2024, 8 institutions reported holding NRX Pharmaceuticals Inc.-CW22 (NRXPW) in their 13F filings, up 2 from Q2 2024. 2 opened new positions and 0 sold out. The largest holders were Virtu Financial LLC ($2K), Truist Financial Corp. ($2K) and Two Sigma Securities, LLC ($783).
- Company
- NRX Pharmaceuticals Inc.-CW22
- CUSIP
- 629444118
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $798 |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 18,215 shares bought and 14,825 shares sold, net +3,390 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Virtu Financial LLC | — | Reduce -16.0% | 34,688 | $2K |
| Truist Financial Corp. | — | No change | 38,965 | $2K |
| Two Sigma Securities, LLC | — | New | 17,400 | $783 |
| Wolverine Asset Management LLC | — | Add +3.4% | 15,392 | $692 |
| UBS Group AG | — | Reduce -35.0% | 15,251 | $686 |
| Johnson Financial Group, Inc. | — | New | 315 | $15 |
| Bank of America Corp. | — | No change | 95 | $4 |
| Tower Research Capital LLC (TRC) | — | No change | 15 | $1 |
"% of holder's portfolio" is NRXPW's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc.-CW22 the manager owns.